Bicara Therapeutics (BCAX) Accumulated Expenses (2023 - 2026)

Bicara Therapeutics' Accumulated Expenses history runs 4 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 59.38% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $1.3 million, a 59.38% decrease from a year earlier, with the FY2023 full-year figure at $8.1 million, changed N/A from the prior year.
• Accumulated Expenses eased to $1.3 million in Q1 2026 per BCAX's latest filing, from $12.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $12.0 million in Q2 2025 and bottomed at $1.3 million in Q1 2026.
• The 4-year median for Accumulated Expenses is $3.2 million (2025), against an average of $5.4 million.
• Biggest YoY gain for Accumulated Expenses was 59.38% in 2026; the steepest drop was 59.38% in 2026.
• Year by year, Accumulated Expenses stood at $8.1 million in 2023, then slumped by 70.2% to $2.4 million in 2024, then jumped by 400.0% to $12.0 million in 2025, then sank by 89.17% to $1.3 million in 2026.
• Per Business Quant, the three latest BCAX Accumulated Expenses figures stand at $1.3 million (Q1 2026), $12.0 million (Q2 2025), and $3.2 million (Q1 2025).